In a phase I clinical trial (NCT01885897), administration of an IL-15 superagonist complex (ALT-803) significantly improved CD8+ T cell and NK cell functions in relapsed patients with leukemia post-allo-HSCT (165). Here, IL15 is linked to leukemia.